CoChat

TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; none of the 33 sources its claims cite is checked for support yet.

Abstract

Cellular mechanisms that mediate steatohepatitis, an increasingly prevalent condition in the Western world for which no therapies are available, are poorly understood. Despite the fact that its synthetic agonists induce fatty liver, the liver X receptor (LXR) transcription factor remains a target of interest because of its anti-atherogenic, cholesterol removal, and anti-inflammatory activities. Here we show that tetratricopeptide repeat domain protein 39B (Ttc39b, C9orf52) (T39), a high-density lipoprotein gene discovered in human genome-wide association studies, promotes the ubiquitination and degradation of LXR. Chow-fed mice lacking T39 (T39−/−) display increased high-density lipoprotein cholesterol levels associated with increased enterocyte ATP-binding cassette transporter A1 (Abca1) expression and increased LXR protein without change in LXR messenger RNA. When challenged with a high fat/high cholesterol/bile salt diet, T39−/− mice or mice with hepatocyte-specific T39 deficiency show increased hepatic LXR protein and target gene expression, and unexpectedly protection from steatohepatitis and death. Mice fed a Western-type diet and lacking low-density lipoprotein receptor (Ldlr−/−T39−/−) show decreased fatty liver, increased high-density lipoprotein, decreased low-density lipoprotein, and reduced atherosclerosis. In addition to increasing hepatic Abcg5/8 expression and limiting dietary cholesterol absorption, T39 deficiency inhibits hepatic sterol regulatory element-binding protein 1 (SREBP-1, ADD1) processing. This is explained by an increase in microsomal phospholipids containing polyunsaturated fatty acids, linked to an LXRα-dependent increase in expression of enzymes mediating phosphatidylcholine biosynthesis and incorporation of polyunsaturated fatty acids into phospholipids. The preservation of endogenous LXR protein activates a beneficial profile of gene expression that promotes cholesterol removal and inhibits lipogenesis. T39 inhibition could be an effective strategy for reducing both steatohepatitis and atherosclerosis.

Overview

CoChat Summary

TL;DR

TTC39B (T39) promotes ubiquitination and degradation of LXR; T39 deficiency stabilizes LXR protein and protects mice from both steatohepatitis and atherosclerosis. The mechanism couples increased cholesterol removal with inhibited SREBP-1 processing and lipogenesis.

Key findings

  • T39 deficiency increased HDL cholesterol by ∼22% in chow-fed mice and by 42% after HF/HC/BS diet, with a 45% increase in ApoA-1; this was linked to increased intestinal Abca1 and post-transcriptional LXR protein induction.
  • In HF/HC/BS-fed T39−/− mice, there was a 4-fold reduction in mortality (p<0.05), decreased ALT, less hepatic TG and cholesteryl ester accumulation, fewer inflammatory foci, less ballooning, and less fibrosis; protection was due to hepatic T39 deficiency and was LXRα-dependent.
  • T39 deficiency inhibited hepatic SREBP-1 processing and reduced lipogenic gene expression and TG synthesis, associated with LXRα-dependent induction of Insig2a, Pcyt1a, Cept1, and Lpcat3, a 30% increase in microsomal phosphatidylcholine, and increased PUFA content in phospholipids.
  • In WTD-fed Ldlr−/−T39−/− mice, T39 deficiency decreased fatty liver, increased HDL, decreased LDL, and reduced atherosclerotic lesion area and lesion complexity.

Methods

  • Mouse models included whole-body T39−/−, tissue-specific Villin-Cre and Albumin-Cre T39fl/fl, Ldlr−/−T39−/−, and Lxrα−/−T39−/− mice; both sexes, 10–20 weeks old, fed chow, HF/HC/BS diet (7.5% cocoa butter, 1.25% cholesterol, 0.5% sodium cholate), or WTD (21% milk fat, 0.15% cholesterol), with blinded measurements.
  • Analyses included lipoprotein/cholesterol/TG assays, Western blotting, gene expression, [3H]cholesterol secretion from enterocytes, NASH histological grading, dietary cholesterol absorption, GC-MS sterol/oxysterol measurement, in vivo lipogenesis, lipidomics, atherosclerosis quantification, ChIP, co-immunoprecipitation, GW3965-affinity LXR pulldown, and LXRα turnover assays.
  • Statistics used mean ± SEM, two-tailed Student t-test or two-way ANOVA with Bonferroni post hoc, p<0.05 significance, and Grubbs’ test for outliers.

Limitations

  • The paper does not state limitations explicitly. Evident from the text: all functional and therapeutic conclusions come from mouse models and cell culture, with no human interventional or clinical validation.
  • Several mechanistic links are proposed rather than fully established; the text notes “there must be a separate more physiologically relevant mechanism regulating SREBP-1 maturation” and that increased PC synthesis/PUFA incorporation “may be a major factor” inhibiting NAFLD.
  • No pharmacological T39 inhibitor was tested in vivo; the therapeutic implication that “T39 inhibition could be an effective strategy” remains untested in this paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/nature18628

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 28 Not checked · 128 Own results and interpretations

100 more claims

Create a free account to see all 156 claims and to verify the 33 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Cited by

See all 106

Metadata

Authors
Hsieh, J., Koseki, M., Molusky, M. M., Yakushiji, E., Ichi, I., Westerterp, M., Iqbal, J., Chan, R. B., Abramowicz, S., Tascau, L., Takiguchi, S., Yamashita, S., Welch, C. L., Di Paolo, G., Hussain, M. M., Lefkowitch, J. H., Rader, D. J., & Tall, A. R.
Affiliations
  • Columbia University (US)
  • Ochanomizu University (JP)
  • SUNY Downstate Health Sciences University (US)
  • University of Pennsylvania (US)
  • The University of Osaka (JP)
Corresponding author
  • Koseki, Masahiro
  • Tall, Alan R.
Venue
Nature
Published
2016-07
Volume
535
Issue
7611
Pages
303-307
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2462155612
Cited by
106
References
38
Citations by year
2026: 4 · 2025: 12 · 2024: 12 · 2023: 8 · 2022: 6 · 2021: 22 · 2020: 13 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 3
FWCI
3.56
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • Japan Society for the Promotion of Science (15K16203)
  • National Heart, Lung, and Blood Institute (RC2HL101864, R01HL119830, P01HL087123, R01HL111398, HL007343, T32HL007343)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK046900, DK-46900, R56DK046900, R29DK046900)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
liver X receptor, atherosclerosis, steatohepatitis, non-alcoholic fatty liver disease, HDL cholesterol, ABCA1, ABCG5/8, dietary cholesterol absorption, SREBP1, Western diet
MeSH terms
ATP Binding Cassette Transporter, Subfamily G, Member 5, ATP Binding Cassette Transporter, Subfamily G, Member 8, Liver X Receptors, Animals, Bile Acids and Salts, Cholesterol, Dietary, Fatty Acids, Unsaturated, Fatty Liver, Female, Gene Expression Regulation, Ligands, Lipoproteins, Lipoproteins, HDL, Cholesterol, HDL, Lipoproteins, LDL, Male, Phosphatidylcholines, Receptors, LDL, ATP-Binding Cassette Transporters, Hepatocytes, Lipogenesis, Atherosclerosis, Mice, Sterol Regulatory Element Binding Protein 1, Ubiquitination, Protein Stability, Orphan Nuclear Receptors, Diet, High-Fat, Proteolysis, ATP Binding Cassette Transporter 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.